For research and educational purposes only. Not medical advice.
Coluracetam Reference
Educational, not medical advice reference for Coluracetam: Nootropic, Cognitive; regulatory status, evidence posture, source review, and schedule notes. Also…
Reference summary
Phase 2a in MDD with comorbid generalized anxiety disorder did not meet primary endpoints; the drug development was discontinued. Mechanistic interest in high-affinity choline uptake (HACU).
- Categories
- Nootropic, Cognitive
- Aliases
- BCI-540, MKC-231
- Evidence posture
- preclinical — Not FDA-approved. Discontinued from clinical development after Phase 2a did not meet endpoints. Community nootropic framing is extrapolation from preclinical HACU mechanism.
- Regulatory status
- No FDA-approved coluracetam drug label. Originally developed by Mitsubishi Tanabe / BrainCells for major depressive disorder; the program was discontinued.
- Content review status
- research reference